| EDITAS MEDICINE DL-,0001 |
| USA |
| Gesundheit |
| US28106W1036 / A2AC4K |
| 8EM (Frankfurt) / EDIT (NASDAQ) |
| FRA:8EM, ETR:8EM, 8EM:GR, NASDAQ:EDIT |
| - |
| https://www.editasmedicin.. |
|
Editas Medicine Inc. is a clinical-stage biotechnology company focused on developing CRISPR-based gene editing therapies for serious diseases. The company harnesses CRISPR technology, which enables precise revision, removal, and replacement of DNA se..
>Volltext.. |
| 232.9 Mio. EUR |
| 188.12 Mio. EUR |
| 33.35 Mio. EUR |
| -73.42 Mio. EUR |
| -93.9 Mio. EUR |
| -1.05 EUR |
| 62.03 Mio. EUR |
| 106.57 Mio. EUR |
| - |
| 3.11 |
| 1.1% |
| 59.39% |
| - |
| - |
| - |
| - |
| EDITAS |
| 26.05.26 |
|